文献速递前列腺癌

多参数磁共振成像促进前列腺癌主动监测中的重新分级

Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer.
PubMed 文献 · BJU Int · 2020-12-10

本研究纳入181例Grade Group 1前列腺癌主动监测患者,至少一次监测mpMRI后行MRI/前列腺活检。中位随访2.2年,PI-RADS≥3病变的病理进展率为37%,PI-RADS 1-2为12%。监测PSA密度和PI-RADS≥3是病理进展的独立预测因素。仅基于MRI进展触发活检可推迟63%的活检,但会漏诊38%的Grade Group≥2升级。

要点

  • 监测mpMRI中PI-RADS≥3与前列腺癌重新分级风险增加相关。
  • 监测PSA密度和PI-RADS≥3是病理进展的独立预测因素。
  • 仅基于MRI进展触发活检可减少活检但漏诊部分升级病例。

核心结论

  • 监测mpMRI中PI-RADS≥3与前列腺癌重新分级风险增加相关。
  • 仅基于MRI进展触发活检可避免大量活检,但会漏诊许多前列腺癌重新分级。
  • 稳定的连续mpMRI与主动监测期间无Grade Group≥3前列腺癌重新分级相关。

研究设计与样本

  • 回顾性分析前瞻性维护的机构审查委员会批准数据库。
  • 纳入181例连续Grade Group 1前列腺癌主动监测患者,至少接受一次监测mpMRI后行MRI/前列腺活检。
  • 对68例接受连续(至少两次)mpMRI/前列腺活检的患者进行亚组分析。
  • 病理进展定义为随访活检升级至Grade Group≥2。

主要发现

  • 基线MRI在34例(19%)患者中进行。
  • 总体队列中位随访2.2年,PI-RADS 1-2病变的病理进展率为12%(6/49),PI-RADS≥3病变为37%(48/129)。
  • 2年无病理进展生存率为84%。
  • 监测前列腺特异性抗原密度(P < 0.001)和监测PI-RADS≥3(P = 0.002)是重新评估MRI/前列腺活检时病理进展的独立预测因素。
  • 连续MRI队列中,无MRI进展组2年无病理进展生存率为95%,MRI进展组为85%(P = 0.02);MRI进展在病理进展组(62%)显著高于无病理进展组(31%)(P = 0.04)。

关键数值与推荐

  • 若连续MRI用于前列腺癌监测且仅基于MRI进展触发活检,63%的前列腺活检可能被推迟,代价是在MRI稳定者中漏诊12%的Grade Group≥2前列腺癌。
  • 相反,该策略会漏诊38%活检升级至Grade Group≥2前列腺癌的患者。

临床怎么用

  • 监测mpMRI中PI-RADS≥3提示重新分级风险增加,应加强监测。
  • 监测PSA密度和PI-RADS≥3可用于风险分层。
  • 仅基于MRI进展触发活检需权衡减少活检与漏诊升级风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the utility of multiparametric magnetic resonance imaging (mpMRI) in the reassessment and monitoring of patients on active surveillance (AS) for Grade Group (GG) 1 prostate cancer (PCa). PATIENTS AND METHODS: We identified, from our prospectively maintained institutional review board-approved database, 181 consecutive men enrolled on AS for GG 1 PCa who underwent at least one surveillance mpMRI followed by MRI/prostate biopsy (PBx). A subset analysis was performed among 68 patients who underwent serial (at least two) mpMRI/PBx during AS. Pathological progression (PP) was defined as upgrade to GG ≥2 on follow up biopsy. RESULTS: Baseline MRI was performed in 34 patients (19%). At a median follow-up of 2.2 years for the overall cohort, the PP was 12% (6/49) for Prostate Imaging Reporting and Data System (PI-RADS) 1-2 lesions and 37% (48/129) for the PI-RADS ≥3 lesions. The 2-year PP-free survival rate was 84%. Surveillance prostate-specific antigen density (P < 0.001) and surveillance PI-RADS ≥3 (P = 0.002) were independent predictors of PP on reassessment MRI/PBx. In the serial MRI cohort, the 2-year PP-free survival was 95% for the No-MRI-progression group vs 85% for the MRI-progression group (P = 0.02). MRI progression was significantly higher in the PP (62%) than in the No-PP (31%) group (P = 0.04). If serial MRI were used for PCa surveillance and biopsy were triggered based only on MRI progression, 63% of PBx might be postponed at the cost of missing 12% of GG ≥2 PCa in those with stable MRI. Conversely, this strategy would miss 38% of those with upgrading to GG ≥2 PCa on biopsy. Stable serial mpMRI correlates with no reclassification to GG ≥3 PCa during AS. CONCLUSION: On surveillance mpMRI, PI-RADS ≥3 was associated with increased risk of PCa reclassification. Surveillance biopsy based only on MRI progression may avoid a large number of biopsies at the cost of missing many PCa reclassifications.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Fujihara A, Iwata T, Shakir A, et al. Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer. BJU Int. 2020. PMID: 33043575. doi:10.1111/bju.15272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。